Menu
← Oncology Approval Tracker
FDA DECISION ·
Opdivo Qvantig
nivolumab + hyaluronidase-nvhy · Bristol Myers Squibb
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Expands subcutaneous monotherapy for eligible MSI-high or mismatch repair-deficient colorectal cancer to patients age 12 years or older who weigh at least 30 kg: after IV nivolumab plus ipilimumab in unresectable or metastatic disease, or after specified fluoropyrimidine, oxaliplatin, and irinotecan in metastatic disease.
LAMPGEN ANALYSIS
Why it matters
The pediatric label extension covers two distinct routes into subcutaneous treatment, with the same age and minimum weight.
What research teams should watch
Verify the dosing weight, biomarkers and qualifying prior regimen; coordinate use with a pediatric oncology team.
PRIMARY RECORDS